Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-oncology Therapy of HER2-negative Gastroesophageal Adenocarcinoma (Siewert I/II): a Multicenter, Open-label, Randomized Controlled, Phase 1b/2 Trial (SCORPIO/NCCES05)

NCT05986227 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT05986227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-oncology Therapy of HER2-negative Gastroesophageal Adenocarcinoma (Siewert I/II): a Multicenter, Open-label, Randomized Controlled, Phase 1b/2 Trial (SCORPIO/NCCES05)
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 1, 2023
Completion date
July 1, 2026
Enrollment
126 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal adenocarcinoma